Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials

AIDS

Volumn 13, Issue 15, 1999, Pages 2075-2082

  Phillips, Andrew N ^a,e   Grabar, Sophie ^b   Tassie, Jean Michel ^b   Costagliola, Dominique ^b   Lundgren, Jens D ^c   Egger, Matthias ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSERM   (France)

^c HVIDOVRE HOSPITAL   (Denmark)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

AIDS; Antiretroviral therapy; Biases; Cohorts; Databases; HIV; Randomized trials

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DATA BASE; DIABETES MELLITUS; DRUG EFFICACY; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; META ANALYSIS; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICS;

ANTI-HIV AGENTS; BIAS (EPIDEMIOLOGY); COHORT STUDIES; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 0032731973     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910220-00010     Document Type: Article

References (34)

1. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
2. Phillips AN, Lee CA, Elford J, et al. Serial CD4 lymphocyte counts and the development of AIDS. Lancet 1991, 337:389-392.
3. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
4. Chalmers I. Unbiased, relevant, and reliable assessments in health care. BMJ 1998, 317:1167-1168.
5. Lundgren JD, Phillips AN, Vella S, et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. J Acquired Immune Defic Syndr 1997, 16:153-160.
6. Phillips AN, Katlama C, Barton S, et al. Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. J Acquired Immune Defic Sydr 1997, 17:239-244.
7. Ledergerber B, von Overbeck J, Egger M, Luthy R. The Swiss HIV Cohort Study: rationale, organisation and selected baseline characteristics. Soz Praeventivmed 1994, 39:387-394.
8. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194-1199.
9. INSERM SC4, Groupe d'Epidémiologie Clinique des CISIH. Base de données clinico-épidémiologique du sujet séropositif suivi à l'hôpital. Manifestations cliniques et traitements à partir de 1989. Bull Epidemiol Hebdomadaire 1995, 35:157-159.
10. Costagliola D, Mary-Krause M, for the Group from Centres d'Information et de Soins de l'Immunodeficience Humaine. Can antiviral agents decrease the occurrence of Kaposi's sarcoma? [letter). Lancet 1995, 346:578.
11. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:1-19.
12. Delta Co-ordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
13. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
14. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1099-1106.
15. 3 or less. N Engl J Med 1997, 337:725-733.
16. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-881.
17. CAESAR Co-ordinating Committee. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
18. Stellbrink H-J on behalf of the Invirase International Phase III Trial (SV-14604) Group. Clinical and survival benefit of saquinavir in combination with zalcitabine and zidovudine in untreated/minimally treated HIV-infected patients. 6th European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 427].
19. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1983.
20. Feinstein A. The role of observational studies in the evaluation of therapy. Stat Med 1984, 3:341-345.
21. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996, 312:1215-1218.
22. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ 1997, 315:1151-1154.
23. Fahy JV, Boushey HA. Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma. Clin Chest Med 1995, 16:715-733.
24. Garrett JE, Lanes SF, Kolbe J, Rea HH. Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity. Thorax 1996, 51:1093-1099.
25. Fleming TR, Prenticie RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med 1994, 13:955-968.
26. Babiker A. Can HIV-1 RNA viral load be used as a surrogate for clinical endpoints in HIV disease? 6th European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, 1997 [Abstract 207].
27. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-1883.
28. Phillips AN, Davey Smith G. The design of prospective epidemiological studies: more subjects or better measurements? J Clin Epidemiol 1993, 46:1203-1211.
29. Graham NMH, Zeger SL, Park LP, et al. Effect of zidovudine and PCP prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991, 338:265-269.
30. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991, 324:1412-1416.
31. Vella S, Giuliano M, Pezzotti P, et al. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA 1992, 267:1232-1236.
32. Lundgren JD, Phillips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994, 271:1088-1092.
33. Graham NMH, Hoover DR, Park LP, et al. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 1996, 124:1031-1038.
34. Dunn D on behalf of the Delta Co-ordinating Committee. Biases in inferring treatment effects from observational data: a case study. AIDS 1998, 12 (Suppl. 4):S15.